Metastatic Castration-resistant Prostate Cancer
Conditions
Brief summary
This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.
Detailed description
This is a two-phase, open-label Phase Ib clinical trial. The first phase plans to enroll 6-12 patients as two cohorts to explore the safety and of TQB3823 tablets combined with abiraterone and prednisone and the recommended dose of phase II of TQB3823. Subjects involved in cohort one accepts TQB3823 treatment during cycle one and then TQB3823 combined with abiraterone and prednisone from cycle two till the disease progression. The second phase plans to enroll a total of 40-60 subjects, aiming to evaluate the safety and efficacy of TQB3823 tablets combined with abiraterone and prednisone.
Interventions
DRUGTQB3823 tablets
TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
Prednisone acetate tablet is a kind of glucocorticoids
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Male patients aged 18 to 85. * Subjects with pathologically proven with prostate adenocarcinoma. * Metastatic disease confirmed by imaging (eg, bone scan and CT/MRI). * The patient's serum testosterone level at the screening visit was ≤ 1.73 nmol/L (50 ng/dL). Patients who did not undergo bilateral orchiectomy required continued ADT \[gonadotropin-releasing hormone analog (LHRHa, agonist/antagonist)\] treatment throughout the study period. * Disease progression during consecutive androgen deprivation therapy (ADT), defined at study entry, as meeting one or more of the following criteria: 1. At least two consecutive PSA elevations separated by at least 1 week, the last result must be at least 1.0 ng/mL. 2. Soft tissue lesion progression as assessed by RECIST 1.1 with or without PSA progression. 3. Bone disease progression assessed by PCWG3, i.e., ≥2 new lesions detected on bone scan, ≥2 new bone lesions other than those previously assessed on reassessment at least 8 weeks later, with ≥2 previously assessed bone lesions still exist, regardless of PSA progression. * Patients must discontinue all prior cancer therapy (except ADT and bone loss prophylaxis) and have recovered to ≤ Grade 1 or baseline (according to the Common Terminology Criteria for Adverse Events) prior to first dose of all acute toxic effects of prior therapy or surgery Version 5.0 \[CTCAE v 5.0\]), with the exception of alopecia and peripheral neuropathy, and the washout period since the last prior systemic or radiation therapy was as follows: 1. At least 4 weeks must have elapsed since enrollment with 5-alpha reductase inhibitors (eg, dutasteride, finasteride), estrogen, and cyproterone. 2. At least 4 weeks must have elapsed from major surgery or radiation therapy to enrollment。 * Laboratory indicators meet the requirements.
Exclusion criteria
* For subjects with brain metastases with symptoms or symptom control for less than 1 month, screening for CNS metastases at baseline is not required unless there are signs and/or symptoms of CNS involvement. * Subjects who have developed or is currently suffering from other malignancies within 3 years, except for cured skin basal cell carcinoma and cervical carcinoma in situ. * Subjects who have accepted botanicals (such as saw palmetto) that may lower PSA levels within 4 weeks before the first dose. * Subjects who have accepted oral targeted drugs within 5 drug half-lives from the first dose (calculated from the end of the last treatment). * Subjects who have not recovered to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 due to the adverse event of prior therapy. * Subjects who have previously accepted CYP17 enzyme inhibitors (including drugs such as abiraterone, TAK-700, TOK-001, and ketoconazole, ect.,) or second generation androgen receptor inhibitors (including enzalutamide, apalutamide, darolutamide , etc.) (mHSPC, nmCRPC stage). 1. The study accept patients who received McRpc-based chemotherapy with CYP17 inhibitors other than abiraterone or second-generation androgen receptor inhibitors or paclitaxel for less than 3 months without disease progression, However, 4 weeks or 5 half-life washing out period is required (whichever is longer). 2. Patients who received abiraterone in the mCRPC phase for less than 3 months and did not progress (no need to stop elution) are allowed in the study, but cannot be enrolled in the phase I cohort of a single drug population in this study. 3. Patients who received ADT+ paclitaxel chemotherapy, ADT+ 1st generation androgen receptor inhibitors (e.g. Flutamide, bicalutamide, nilutamide, etc.), ADT+ERBT (external radiation therapy) in mHSPC phase will be acceptable in the study, provided that they met the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicity (DLT) | Up to 4 weeks | The relevant adverse reactions occurred within the first cycle |
| Recommended phase II dose (RP2D) | Up to 8 weeks | The dose of TQB3823 tablet which is recommended to use during phase II clinical trial |
| The ratio of subject radiographic progression-free survival for 12 months | For 12 months | Proportion of subjects without disease progression assessed by radiology within 12 months |
| Adiographic progression-free survival (rPFS) | Up to 24 months | rPFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause evaluated by radiological examination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical benefit rate (CBR) | Up to 24 months | Proportion of subjects with clinical benefit |
| Duration of Response (DOR) | Up to 24 months | The time when the participants first achieved CR or PR to disease progression or death from any cause. |
| time to bone-related event | Up to 24 months | Time to progression of bone disease in subjects |
| Time to PSA progression | Up to 24 months | Time to raise of PSA in subjects |
| The ratio of subject radiographic progression-free survival for 12 months | For 6 months | Proportion of subjects without disease progression assessed by radiology within 6 months |
| Peak concentration (Cmax) | Cycle 1 day 1 and cycle 1 day 28 Before administration, and 1, 2, 4, 6, 8, 11, 12, 24 hours after administration. Cycle 1 day 14 before administration,(each cycle is 28 days) | Maximum plasma drug concentration |
| Half-life /T1/2 | Cycle 1 day 1 and cycle 1 day 28 Before administration, and 1, 2, 4, 6, 8, 11, 12, 24 hours after administration. Cycle 1 day 14 before administration,(each cycle is 28 days) | The time it takes for the drug's concentration in the body to drop by half |
| Adverse event rate | Baseline up to 96 weeks | The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs). |
| Peak time (Tmax) | Cycle 1 day 1 and cycle 1 day 28 Before administration, and 1, 2, 4, 6, 8, 11, 12, 24 hours after administration. Cycle 1 day 14 before administration,(each cycle is 28 days) | The time to peak concentration |
| The ratio of prostate specific antigen (PSA) reduction | Up to 24 months | Proportion of subjects with reduction of PSA |
| Overall response rate (ORR) based on 2014 Lugano | Up to 24 months | Percentage of participants achieving complete response (CR) and partial response (PR). |
| Overall survival (OS) | Up to death | OS defined as the time from randomization until the death from any cause |
Countries
China
Outcome results
None listed